Overview
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
Status:
Recruiting
Recruiting
Trial end date:
2022-09-30
2022-09-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study plans to learn more about the effects of levetiracetam (LEV) on brain activity and cognition in schizophrenia and schizoaffective disorder. Levetiracetam is an anti-seizure drug, also called an anticonvulsant.Phase:
Phase 1/Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
VA Office of Research and DevelopmentTreatments:
EtiracetamLevetiracetam
Piracetam
Criteria
Inclusion Criteria:- Diagnosis of schizophrenia or schizoaffective disorder
- Good general health
- Normal vital signs (blood pressure, pulse, respiration)
Exclusion Criteria:
- Substance abuse
- Significant neurological disorders
- Significant head trauma/injury
- Pregnancy
- MRI-specific exclusion criteria, e.g.,:
- claustrophobia
- weight>400 lbs
- metal in the body